en · de · es
nad-notes.peptides6155.com › Data › Analytical Detection And Regulatory Status — Background and Details

Analytical Detection And Regulatory Status — Background and Details

By Editorial Desk · published 2026-06-23 · last reviewed 2026-08-01 · Data

NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useInvestigational status in most countries
Sports statusProhibited by WADAClassified as non-approved or metabolic modulator
Common analytical methodLC-MS/MSUsed for trace detection in biological samples
Typical test matricesUrine and bloodSample choice depends on testing program
Human trial dataNone publishedEffects and safety are not established

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Related pages on this site

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Notes from published material

=== Prey === Rattlesnakes typically consume mice, rats, rabbits, ground squirrels, gophers, prairie dogs, ground-nesting birds and other small animals (such as lizards, frogs, toads and occasionally American mink and weasels). They lie in wait for their prey, or hunt for it in holes. The rattlesnake's defence and hunting mechanisms are bound to its physiology and its environment. More importantly environmental temperature can influence the ability of ectotherms. The prey is killed quickly with a venomous bite as opposed to constriction. If the bitten prey moves away before dying, the rattlesnake can follow it by its scent. When it locates the fallen prey, it checks for signs of life by prodding with its snout, flicking its tongue, and using its sense of smell. Once the prey has become incapacitated, the rattlesnake locates its head by odors emitted from the mouth. The prey is then ingested head first, which allows wings and limbs to fold at the joints in a manner that minimizes the girth of the meal. The gastric fluids of rattlesnakes are extremely powerful, allowing for the digestion of flesh and bone. Optimal digestion occurs when the snake maintains a body temperature between 80 and 85 °F (27 and 29 °C). If the prey is small, the rattlesnake often continues hunting. If the meal was adequate, the snake finds a warm, safe location in which to coil up and rest until the prey is digested. Feeding habits play an important ecological role by limiting the size of rodent populations, which prevents crop damage and stabilizes ecosystems.

Creatine is an organic acid naturally occurring in the body (and in red meats) that supplies energy to muscle cells for short bursts of energy (as required in lifting weights) via creatine phosphate replenishment of ATP. Scientific studies have shown that creatine supplementation can increase the consumer's strength, energy during performance, muscle mass, and recovery times after exercise. In addition, recent studies have also shown that creatine improves brain function and reduces mental fatigue. Some studies have suggested that consumption of creatine with protein and carbohydrates can have a greater effect than creatine combined with either protein or carbohydrates alone. While generally considered safe, long-term or excessive consumption of creatine may have an adverse effect on the kidneys, liver, or heart and should be avoided if any pre-existing conditions affecting these organs exist.

=== Effect on French colonies === The Viet Minh victory in the war had an inspirational effect to independence movements in various French colonies worldwide, most notably the FLN in Algeria. The Algerian War broke out on 1 November 1954, only six months after the Geneva Conference. Benyoucef Benkhedda, later became the head of the Provisional Government of the Algerian Republic, praised the Viet Minh feat at Dien Bien Phu as "a powerful incentive to all who thought immediate insurrection the only possible strategy". The French Communist Party played an even stronger role by supplying the National Liberation Front (FLN) rebels with intelligence documents and financial aid. They were called "the suitcase carriers" (les porteurs de valises). In the French news, the Indochina War was presented as a direct continuation of the Korean War, where France had fought: a UN French battalion, incorporated in a U.S. unit in Korea, was later involved in the Battle of Mang Yang Pass of June and July 1954. In an interview taped in May 2004, General Marcel Bigeard (6th BPC) argues that "one of the deepest mistakes done by the French during the war was the propaganda telling you are fighting for Freedom, you are fighting against Communism", hence the sacrifice of volunteers during the climactic battle of Dien Bien Phu. In the latest days of the siege, 652 non-paratrooper soldiers from all army corps from cavalry to infantry to artillery dropped for the first and last time of their life to support their comrades.

Sources: en.wikipedia.org

Background from the literature

=== Metabolism === Cholesterol is recycled in the body. The liver excretes cholesterol into biliary fluids, which are then stored in the gallbladder from where they are excreted in a non-esterified form (via bile) into the digestive tract. Typically, about 50% of the excreted cholesterol is reabsorbed by the small intestine back into the bloodstream.

During his 2022 gubernatorial campaign, Moore said he supported the Inclusive Schools Act, a bill introduced in the 2022 legislative session that banned schools from discriminating against students based on their sexual orientation and gender identity. He also supported the Trans Health Equity Act, a bill that would have required the state's Medicaid program to cover gender-affirming treatments. In December 2022, Moore praised the signing of the Respect for Marriage Act, which codifies same-sex and interracial marriage rights. On March 31, 2023, Moore became the first Maryland governor to recognize International Transgender Day of Visibility when he issued an official proclamation. In May 2023, Moore signed the Trans Health Equity Act into law and allowed a bill furthering an earlier repeal of the state's sodomy law to become law without his signature. In June 2023, he signed an executive order to protect people or entities that provide gender-affirming care from legal punishments by other states. During the 2024 legislative session, Moore signed into law the Trans Shield Act, which prevents states with anti-trans laws from prosecuting patients or entities within Maryland for providing gender-affirming care. In May 2025, Moore signed into law a bill decriminalizing the spread of HIV.

UPMC Kildare Hospital is a 39-bed private hospital located in County Kildare, Ireland (founded in 1985 as Clane General Hospital). UPMC acquired the hospital in November 2019 in partnership with the Institute of Eye Surgery.

== History == Loren Pickart (1938–2023) isolated the copper peptide GHK-Cu from human plasma albumin in 1973. It was noticed that liver tissue obtained from patients aged 60 to 80 years had an increased level of fibrinogen. However, when liver cells from old patients were incubated in the blood from the younger group, the older cells started functioning in nearly the same way as the younger liver tissue. It turned out that this effect was due to a small peptide factor that behaved similarly to the synthetic peptide glycyl-L-histidyl-L-lysine (GHK). Pickart proposed that this activity in human plasma albumin was a tripeptide glycyl-L-histidyl-L-lysine and that it might function by chelating metal ions. In 1977, the growth modulating peptide was shown to be a glycyl-L-histidyl-L-lysine. It is proposed that GHK-Cu modulates copper intake into cells.

Sources: en.wikipedia.org

Further detail

People who have ancestry from Sub-Saharan Africa, Asia, or Latin America are more likely to develop a keloid. Among ethnic Chinese in Asia, the keloid is the most common skin condition. In the United States, keloids are more common in African Americans and Hispanic Americans than European Americans. Those who have a family history of keloids are also susceptible since about 1/3 of people who get keloids have a first-degree blood relative (mother, father, sister, brother, or child) who also gets keloids. This family trait is most common in people of African and/or Asian descent. The development of keloids among twins also lends credibility to the existence of a genetic susceptibility to develop keloids. Marneros et al. (1) reported four sets of identical twins with keloids; Ramakrishnan et al. also described a pair of twins who developed keloids at the same time after vaccination. Case series have reported clinically severe forms of keloids in individuals with positive family history and black African ethnic origin.

=== X-ray spectrometer === The most practical application of 244Cm—though rather limited in total volume—is as an α-particle source in alpha particle X-ray spectrometers (APXS). These instruments were installed on the Sojourner, Mars, Mars 96, Mars Exploration Rovers and Philae comet lander, as well as the Mars Science Laboratory to analyze the composition and structure of the rocks on the surface of planet Mars. APXS was also used in the Surveyor 5–7 moon probes but with a 242Cm source. An elaborate APXS setup has a sensor head containing six curium sources with a total decay rate of several tens of millicuries (roughly one gigabecquerel). The sources are collimated on a sample, and the energy spectra of the alpha particles and protons scattered from the sample are analyzed (proton analysis is done only in some spectrometers). These spectra contain quantitative information on all major elements in the sample except for hydrogen, helium and lithium.

γ-Butyrolactone (GBL) or gamma-butyrolactone is an organic compound with the formula O=CO(CH2)3. It is a hygroscopic, colorless, water-miscible liquid with a pleasant odor. It is the simplest 4-carbon lactone. It is mainly used as an intermediate in the production of other chemicals, such as N-methyl-2-pyrrolidone. In humans, GBL acts as a prodrug for gamma-hydroxybutyric acid (GHB) and is often used as a recreational drug. GHB acts as a central nervous system (CNS) depressant with effects similar to those of barbiturates.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Why is SR9009 prohibited in sport?

Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.

How is SR9009 detected in samples?

Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

Network